|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006754,
umls-concept:C0006826,
umls-concept:C0007131,
umls-concept:C0045093,
umls-concept:C0079083,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0920321,
umls-concept:C1176309,
umls-concept:C1443643,
umls-concept:C1513822,
umls-concept:C1880171
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-1
|
|
pubmed:abstractText |
Bortezomib is a small-molecule proteasome inhibitor with single-agent activity in patients with non-small cell lung carcinoma (NSCLC) and synergy with gemcitabine in preclinical studies. The combination of gemcitabine and carboplatin is an accepted first-line treatment for advanced NSCLC. We conducted a phase I study of gemcitabine and carboplatin in combination with bortezomib.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
68-74
|
|
pubmed:dateRevised |
2008-5-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18166843-Adult,
pubmed-meshheading:18166843-Aged,
pubmed-meshheading:18166843-Antimetabolites, Antineoplastic,
pubmed-meshheading:18166843-Antineoplastic Agents,
pubmed-meshheading:18166843-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18166843-Boronic Acids,
pubmed-meshheading:18166843-California,
pubmed-meshheading:18166843-Carboplatin,
pubmed-meshheading:18166843-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18166843-Deoxycytidine,
pubmed-meshheading:18166843-Dose-Response Relationship, Drug,
pubmed-meshheading:18166843-Drug Administration Schedule,
pubmed-meshheading:18166843-Drug Synergism,
pubmed-meshheading:18166843-Drug Therapy, Combination,
pubmed-meshheading:18166843-Humans,
pubmed-meshheading:18166843-Lung Neoplasms,
pubmed-meshheading:18166843-Middle Aged,
pubmed-meshheading:18166843-Neoplasm Staging,
pubmed-meshheading:18166843-Neutropenia,
pubmed-meshheading:18166843-Proteasome Endopeptidase Complex,
pubmed-meshheading:18166843-Pyrazines,
pubmed-meshheading:18166843-Thrombocytopenia,
pubmed-meshheading:18166843-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
